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To conduct a systematic review of the risks of short-term
outcomes after major treatments for clinically localised prostate
cancer. MEDLINE, EMBASE and the Cochrane Library were
searched from 2004 to January 2013. Study arms that included
≥100 men with localised prostate cancer in receipt of surgery,
radiotherapy or active surveillance and reported symptomatic
and quality-of-life (QoL) data from 6 to 60 months after
treatment were eligible. Data were extracted by one reviewer
and checked by another. In all, 64 studies (80 treatment
cohorts) were included. Most were single treatment cohorts
from the USA or Europe. Radiotherapy was the most common
treatment (40 cohorts, including 31 brachytherapy cohorts)
followed by prostatectomy (39 cohorts), with only one active
surveillance cohort. Most frequently measured symptoms were
urinary, followed by sexual, and bowel; QoL was assessed in
only 17 cohorts. Most studies used validated measures,
although poor data reporting and differences between studies
meant that it was not possible to pool data. Data on the precise
impact of short-term symptomatic and QoL outcomes after
treatment for localised prostate cancer are of insufﬁcient
quality for clear guidance to men about the risks to these
aspects of their lives. It is important that future studies focus
on collecting core outcomes through validated measures and
comply with reporting guidelines, so that clear and accurate
information can be derived for men considering screening or
treatment for prostate cancer.
Keywords
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Introduction
Screening for prostate cancer remains controversial because
testing for PSA leads to the diagnosis of large numbers of
tumours that may not become life-threatening or clinically
apparent during a man’s lifetime. Current management
options for clinically localised prostate cancer include radical
surgery and radiotherapy (RT) treatments with curative
intent, which risk damage to urinary, bowel, and sexual
functioning, or active monitoring or surveillance that aim to
avoid radical treatment and its consequences in the short-
term, but may miss the opportunity for cure. Randomised
controlled trials (RCTs) of screening [1,2] and treatment [3,4]
have focused their major reports on rates of mortality and the
incidence of metastases and clinical disease progression, with
relatively little attention devoted to symptomatic and quality-
of-life (QoL) impacts.
Many observational studies have provided data attempting to
specify and quantify symptomatic and QoL outcomes.
Systematic reviews published in 2008 and 2011 included all
outcomes, but, as with the major RCTs, focused particularly
on clinical outcomes [5,6]. The reviews of symptomatic and
QoL outcomes concluded that all treatments – including
androgen-deprivation therapy (ADT), radical prostatectomy
(RP) and RT – caused urinary, bowel, or sexual dysfunction
[5,6]. The 2008 review added that studies did not report
consistent deﬁnitions for outcomes, or report similar follow-
up periods, and that they varied in whether baseline rates
were assessed, and what measures were used [5]. In the 2011
review, particular studies were identiﬁed that showed that RP
resulted in higher levels of erectile dysfunction and urinary
incontinence than RT, and that RT was also associated with
bowel dysfunction [6]. Both reviews noted that symptomatic
and QoL data were variably assessed and that detailed
conclusions were difﬁcult because of limitations in the
evidence [5,6].
A more recent review was undertaken of the use of validated
patient-reported outcome measures (PROMs) in large
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prospective studies, with the aim of developing a core
outcome set [7]. This found that the studies were difﬁcult to
interpret because of poor reporting and patient selection
related to cohort design, but recommended that ﬁve domains
should be studied for assessment of treatments for localised
disease: urinary incontinence, urinary obstruction and
irritation, bowel-related symptoms, sexual dysfunction, and
hormonal symptoms [7].
Since these reviews were undertaken, there has been
increasing attention to the importance of collecting patient-
reported symptomatic and QoL data, particularly through
standardised and validated PROMs [8]. In addition, new
treatment modalities, such as laparoscopic and robotic
surgery, brachytherapy (BT) and active surveillance/
monitoring, have become more widespread, mostly with the
aim of improving patient outcomes by reducing short-term
symptomatic side-effects.
We undertook a systematic review of the published literature
focusing on the assessment of symptomatic and QoL
outcomes, including methods of measurement as well as the
use of validated PROMs. The aim was to build on the
previous reviews to provide clarity about the risks of short-
term (6–60 months) outcomes after the major treatments for
clinically localised, PSA-detected prostate cancer, and, where
possible, to pool data from PROMs using meta-analysis.
Methods
This review followed guidance published by the Centre for
Reviews and Dissemination and the Cochrane Collaboration
[9,10]. We established a protocol for the review (available
from the authors on request).
Data sources and searches
The previous review by Wilt et al. 2008 [5], evaluated studies
published up to 2004; this review therefore only considered
the literature published subsequently. Studies were identiﬁed
by searching MEDLINE, the Excerpta Medica database
(EMBASE) and The Cochrane Library [Cochrane Database of
Systematic Reviews, the Cochrane Central Register of
Controlled Trials, Database of Abstracts of Reviews of Effects
(DARE) and Health Technology Assessment (HTA)
databases)], all from 2004 to January 2013. We combined text
word and Medical Subject Headings (MeSH) search terms for
prostate cancer, the treatments and outcomes of interest
(Appendix S1). We excluded studies published in languages
other than English, letters or commentaries. Search results
and full text articles were independently assessed for inclusion
by two reviewers; disagreements were resolved through
consensus or referral to a third reviewer. The intention was
to update searches for outcomes for which sufﬁcient data
were available to permit meta-analysis.
Study selection
Study arms that included ≥100 men with clinically diagnosed
localised prostate cancer and prospectively collected
symptomatic and QoL outcome data (6–60 months) were
eligible. We included studies of men with clinically localised
prostate cancer – TNM stage T1 or T2 [11] in ≥95% of
participants. We included cohorts with the following
treatments: RP (robot-assisted, laparoscopic or open), RT
(including external-beam RT (EBRT) and BT], active
surveillance or watchful waiting. ADT was allowed in
combination with other treatments as adjuvant or neoadjuvant
therapy. We deﬁned short-term outcomes as those occurring
between 6 and 60 months after primary treatment for prostate
cancer. Short-term symptomatic and QoL outcomes included
those relating to urinary, bowel, hormonal or sexual function
or bother, mood, general QoL, or generic health status.
We excluded studies involving only a single surgeon or the
ﬁrst cases of a new surgical treatment in a hospital (so called
‘learning curve’ studies). Studies were also excluded if men
received a combination of treatments, if there was insufﬁcient
information to categorise the prostate cancer stage, when it
was not possible to extract outcome data separately for
different treatments, or if studies did not report baseline
values for the outcomes of interest.
Data extraction and quality assessment
Data extraction was performed by one reviewer and checked
by a second; disagreements were resolved through consensus
or referral to the review team. We extracted data on: study
design, year, country, number of centres, participant
characteristics, type of treatment, duration of follow-up,
PROM used or other measure, and the short-term
symptomatic and QoL outcomes measured. All included
studies were single or multiple treatment cohorts or were
analysed as such and so were considered at high risk of bias.
A formal quality assessment was therefore not conducted.
Data synthesis and analysis
We grouped outcomes into the following domains: urinary,
sexual, bowel, hormonal, anxiety, depression, coping, QoL,
and ‘other’. We summarised the number of treatment cohorts
that reported each different outcome within these domains,
separately for each of the different treatments. For outcomes
reported by four or more treatment cohorts we investigated
whether it was possible to conduct further analyses for these
outcomes. If further analysis was possible, we intended to
estimate summary mean differences and relative risks
together with 95% CIs using random-effects models. Where
meta-analysis was not possible, we summarised the reasons
for this. For the most commonly evaluated symptoms (sexual
potency and urinary continence), we reported the range in
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the proportion of patients who reported these symptoms at 6,
12 and 24 months of follow-up stratiﬁed according to
treatment.
Results
The searches identiﬁed 12 355 references from 2004 to 2013
of which 726 were considered potentially relevant based on
title and abstract screening. In all, 64 studies evaluating 80
treatment cohorts were included: two RCTs [12,13], nine
multiple treatment cohorts [14–22], and 53 single treatment
cohorts [23–75] (Fig. 1). The two RCTs compared different
forms of the same treatment (BT [12] and EBRT [13]). In all,
35 studies were from the USA, 21 from Europe, ﬁve from
Canada, four from Asia, two from Australia, one from Israel,
and two were multi country (one from the USA and Spain
and one from the USA and Canada). RP was the most
commonly evaluated treatment: 24 cohorts assessed open RP,
10 assessed laparoscopic RP, four assessed robot-assisted RP,
and one assessed mixed open RP and robot-assisted/
laparoscopic RP. BT was assessed in 31 cohorts, RT
(including EBRT, conformal and stereotactic body RT) in
nine cohorts. Only one cohort assessed active monitoring
[60]. Where reported, the age range was 36–91 years across
studies, the median age range was 56–60 years and the mean
age range was 57–70 years. Details of included studies are
provided in Appendix S2 [12–75].
The most frequently reported outcomes were urinary
symptoms: 55 of the 64 studies (67/80 cohorts) reported some
measure of urinary function (Table 1) [29,81–96]. Of these, 49
studies measured urinary symptoms using a validated PROM,
including the IPSS (22 cohorts), Expanded Prostate cancer
Index Composite (EPIC; 15 cohorts), AUA Symptom Index
(AUASI; 14 cohorts), and the University of California, Los
Angeles Prostate Cancer Index (UCLA PCI; 13 cohorts). Other
validated scales such as the European Organisation for
Research and Treatment of Cancer quality of life questionnaire
prostate speciﬁc 25-item (EORTC QLQ-PR25) and the
International Continence Society (ICS)Male questionnaire were
reported in less than ﬁve cohorts. Sexual symptoms were also
reported by most studies, with 43 studies (55 cohorts)
reporting some measure of sexual function, 36 using validated
PROMs. Most studies reported sexual function using validated
PROMs such as the EPIC (16 cohorts), UCLA PCI (12
cohorts), or International Index of Erectile Function (IIEF; 10
cohorts). Various non-validated measures were also used to
assess urinary and sexual outcomes. Bowel and hormonal
symptoms were less commonly reported with only 14 studies
(18 cohorts) reporting some measure of bowel functioning and
six studies (10 cohorts) reporting hormonal function, all using
validated PROMs (EPIC and EORTC QLQ-PR25). Of the
studies that reported bowel function, 10 assessed EBRT or BT,
and eight RP, meaning that nine of the RT cohorts did not
report any measure of bowel function. QoL was reported in 12
studies (17 cohorts), most commonly using a variation of the
36-item short-form health survey (SF-36; 12 cohorts), the
EORTC QLQ-30-item core (C30; ﬁve cohorts) or the
Functional Assessment of Cancer Therapy – General (FACT-
G) and FACT – Prostate (FACT-P, three cohorts). Other
measures such as anxiety [Memorial Anxiety Scale for Prostate
Cancer (MAX-PC) and State-Trait Anxiety Inventory six-item
(STAI-6)], depression [Center for Epidemiologic Studies
Depression scale (CES-D)], and coping (Utrecht Coping List)
were each reported in two or fewer cohorts.
Studies often reported on multiple outcomes, appropriately
using different dimensions of the same scale such as the
EPIC, UCLA PCI or EORTC QLQ. Thirteen studies used the
EPIC, and of those four provided data for all four
components of the measure (urinary, bowel, hormone, sexual
symptoms), three provided data for three components
(urinary, bowel, sexual symptoms), two provided data for two
components (urinary and bowel or urinary and sexual
symptoms), and four assessed single components of the tool
(urinary in one, sexual in three). Eleven studies used the
UCLA PCI, and two assessed all three components (urinary,
bowel, sexual), six assessed two components, and three
assessed single components. Five studies assessed the EORTC,
but none assessed all ﬁve components (urinary, bowel, sexual,
hormone, QoL); three assessed four components and two
assessed single components (hormonal or QoL).
We investigated whether studies had reported outcome data
sufﬁciently consistently to permit pooling. For pooling to be
possible we speciﬁed that a minimum of four treatment
cohorts were required to report a single outcome for a
speciﬁed treatment. We found that it was not possible to pool
data for any outcome for any treatment. Reasons why pooling
was not possible included presentation of a mixture of
continuous and dichotomous outcomes, lack of reporting of
SD or other measure of variance for continuous outcome,
reporting of outcomes after different periods of follow-up,
assessing different components/versions of a measure, only
reporting data graphically or reporting different measures on
graphs, and using different thresholds to dichotomise results.
Data suitable for pooling for any single outcome were
provided only by two cohorts at most. Table 2 [81–84,86]
provides an overview of reasons why pooling was not possible
for each outcome, stratiﬁed according to treatment.
As data were not appropriate for pooling, we summarised the
range of incidence of urinary and sexual symptoms at 6, 12
and 24 months of follow-up, stratiﬁed according to treatment
(Table 3). It was not possible to provide this information for
other outcomes such as bowel or QoL outcomes, as
dichotomous data were not provided by a sufﬁcient number
of studies. Most studies that dichotomised data on urinary
symptoms provided data that allowed us to calculate the
proportion of continent patients, although the exact way in
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which this was deﬁned varied considerably across studies, as
did the way in which it was assessed, so detailed conclusions
could not be easily drawn.
In general terms, there were a larger proportion of continent
patients in the BT- and EBRT-treated cohorts compared with
the RP-treated cohorts, although the number of continent
patients tended to improve with time for all treatment
groups. There was no difference between open and
laparoscopic/robot-assisted RP until 24 months, when the
number of continent patients was greater with laparoscopic/
robot-assisted RP, although cohort numbers were small.
Sexual symptoms were assessed as the number of potent men,
although the exact deﬁnition of this also varied with the most
common being ‘erection sufﬁcient for intercourse’ or ‘return
to baseline sexual function’. Many studies restricted this
analysis to patients with ‘normal’ sexual function at baseline.
Differences between treatment groups were less clear for
potency, although there was some suggestion that this was
11629 excluded reports
726 Full reports assessed 
64 studies (80 treated cohorts) included: 
2   RCTs
9    multiple treatment cohorts 
53  single treatment cohorts 
662 reports excluded
278   More than 5% T3 or insufficient information on stage
73 <100 per arm or N not stated 
54   No baseline data  
46    Single surgeon study or learning curve report 
39   Follow‐up <6 months
35   Retrospective  
34   Not English language 
29   Follow‐up >5 years 
27   Comment, Letter, or review 
27   Outcome data not of interest  
11   Brachytherapy and radiotherapy combined 
4   Treatment not relevant  
3   Duration of follow‐up not specified  
1   Qualitative research 
1   Duplicate 
15  Mixed or Robotic 
prostatectomy:  
10  Laparoscopic 
prostatectomy  
4     Robotic prostatectomy   
1     Mixed open and robotic 
laparoscopic prostatectomy 
9 Radiotherapy
5  Conformal radiotherapy 
3  External beam   
radiotherapy  
1  Stereotactic body 
radiotherapy
31  Brachytherapy 1  Active  
monitoring  
24 Radical
prostatectomy  
Records identified through database
searching (duplicates removed) 
12355 titles and abstracts screened 
Fig. 1 Flow of reports through the review process.
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lower with RP than EBRT and BT. As with continence,
potency improved a little after RP. It remained similar over
time after EBRT and BT. However, it should be noted that no
formal statistical comparisons between treatment groups was
possible due to the differences in the way that symptoms
were measured between studies. Any comparisons are also
based on evaluations within single treatment cohorts rather
than within study comparisons.
Discussion
The present review identiﬁed 64 studies evaluating short-term
symptomatic and QoL outcomes in 80 cohorts assessing RP
(39 cohorts), RT (40 cohorts) or active surveillance (one
cohort) for localised prostate cancer. Most studies were single
treatment cohorts (53 studies) and most were undertaken in
the USA (40) or Europe (21). Patients involved in these
studies were mostly aged 56–70 years, which is the age-group
suitable for these radical interventions. However, the ages
actually ranged from 36 to 91 years, which suggests that some
studies included patients who might not be able to beneﬁt
from treatment. The most commonly assessed symptomatic
outcomes were related to the urinary tract, with 55 studies
reporting at least one measure of urinary function, 49 of
which used a validated PROM to assess some aspect of
urinary function. Sexual function symptoms were assessed in
43 studies, with validated PROMs used in 36 (the EPIC in 16
cohorts, the UCLA-PCI in 12, and the IIEF in nine). Bowel
symptoms were assessed mostly through the EPIC (13
cohorts), with the EORTC QLQ (four) and the UCLA PCI
(two). QoL was assessed in only 12 studies in total, with 10
cohorts using a version of the SF-36, ﬁve the EORTC QLQ
and three the FACT-G and FACT-P. Other outcomes such as
Table 1 Number of treatment cohorts that reported each short-term outcome measure.
Domain Outcome measure and
reference to measure
Number of treatment cohorts
Total RP Laparoscopic or
robot-assisted RP
RT BT Active
monitoring
Urinary AUASI [81] 14 4 1 2 7
IPSS [82] 22 1 3 18
EPIC: Urinary symptoms [83] 15 4 4 5 2
UCLA PCI: Urinary symptoms [84] 13 7 5 1
EORTC QLQ-PR25: Urinary symptoms [85] 4 1 3
ICSMale 3 2 1
Patient-completed, non-validated 3 2 1
Other, non-validated 8 4 2 2
Sexual EPIC: Sexual symptoms [83] 16 6 4 4 2
UCLA PCI: Sexual symptoms [84] 12 6 5 1
IIEF/IIEF-5 [86, 87] 10 5 2 3
EORTC QLQ-PR25: Sexual symptoms [85] 4 1 3
SAQ Q [88] 4 1 2 1
SHIM [89] 4 1 3
Patient-completed, non-validated 3 1 2
Other, non-validated 5 1 1 3
Bowel EPIC: Bowel symptoms [83] 13 4 2 5 2
EORTC QLQ-PR25: Bowel symptoms [85] 4 1 3
UCLA PCI: Bowel symptoms [84] 2 1 1
Non-validated: Bowel symptoms 1 1
Hormonal EPIC: Hormonal symptoms [83] 8 3 3 2
EORTC QLQ-PR25: Hormonal Treatment
related symptoms [85]
2 1 1
QoL EORTC QLQ-C30 [90] 5 2 3
FACT-G [91] 3 1 1 1
FACT-P [92] 3 1 1 1
SF-36 various versions 12 6 1 1 4
QoL not speciﬁed 1 1
Anxiety MAX-PC [93] 1 1
STAI-6 [94] 1 1
Depression CES-D [95] 2 1 1
Coping Utrecht Coping List [96] 1 1
Other Symptoms and QoL [29] 1 1 1
Total 87 24 15 13 34 1
AUASI, AUA Symptom Index; CES-D, Center for Epidemiologic Studies Depression; EORTC QLQ, European Organisation for Research and Treatment of Cancer quality of life
questionnaire; EPIC, Expanded Prostate Cancer Index; FACT-G, Functional Assessment of Cancer Therapy – General; FACT-P, Functional Assessment of Cancer Therapy –
Prostate; ICS, International Continence Society Male Questionnaire; IIEF, International Index of Erectile Function; MAX-PC, Memorial Anxiety Scale for Prostate Cancer; SAQ Q,
Sexual Adjustment Questionnaire; SF-36, 36-item short-form health survey; SHIM, Sexual Health Inventory for Men; STAI-6, State Trait Anxiety Inventory six-item; UCLA PCI,
University of California, Los Angeles Prostate Cancer Index.
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Table 2 Reasons why meta-analysis was not possible for each outcome stratiﬁed according to treatment.
Domain Outcome
measure and
reference to
measure
Treatment Number of
cohorts
Meta-
analysis
possible
Reason
Urinary AUASI [81] RP 4 No No SD or measure of variance: 1 cohort
Follow-up time varied between studies: 12 months in 2 cohorts, 6 months in 2 cohorts.
Different component of AUASI reported: AUA-7 symptom index (1 cohort), AUSASI
obstruction (1 cohort), AUA symptom score (1 cohort), urinary bother, dysfunction
and limitation(1 cohort)
BT 7 No No SD or other measure of variance: 3 cohorts
3 components of the score not overall AUASI score: 1 cohort
Mean and SD overall AUASI score at baseline, 6 and 12 months: 3 cohorts
IPSS [82] BT 18 No Only reported data graphically: 10 cohorts; of these only 2 reported means and SDs,
others reported data as medians with IQR and range or means and medians alone.
Dichotomised data using different thresholds: 3 cohorts
Continuous data (medians or means) with no measure of variation: 5 cohorts
EPIC: Urinary
symptoms [83]
RP 4 No Dichotomous data: 1 cohort
Continuous data: 4 cohorts
No SD or measure of variance: 1 cohort
Urinary summary score at 6 and 12 months: 2 cohorts
Urinary function irritation/obstruction: 2 cohorts (1 graph only), 1 using EPIC-26,
1 EPIC version not reported
Urinary function/incontinence: 2 cohorts (1 graph only), 1 using EPIC-26, 1 EPIC
version not reported
Laparoscopic
or robot-
assisted RP
4 No Continuous data: 2 cohorts
Subgroup data only, no overall data: 1 cohort
Both reported data at 12 months based on the same EPIC subscales
Dichotomous data: 2 cohorts
Both reported number with no pads at 6 and12 months, other outcomes varied
RT 5 No Continuous data: 5 cohorts
Data only available graphically: 3 cohorts
No SD or measure of variance: 1 cohort
Dichotomous data: 1 cohort
UCLA PCI:
Urinary
symptoms [84]
EPIC:
Sexual
symptoms [83]
RP 7 No No SD or measure of variance: 1 cohort
Mean, SD at 6 and 12 months for urinary function: 2 cohorts
Dichotomous/categorical data using different thresholds: 4 cohorts
Data reported for different time points: 24 month (2 cohorts), 12 months (1 cohort),
6 months (1 cohort), 48 months (1 cohort)
Laparoscopic
or robot-
assisted RP
5 No Dichotomised data using different thresholds: 4 cohorts
Continuous data: 1 cohort
Sexual RP 6 No Dichotomous data: 2 cohorts, 1 used EPIC-26 and 1 used EPIC-50
Continuous data: 5 cohorts
Different measures: EPIC sexual subscale, bother and function (3 cohorts) – reported
at 6 and12 months in 2 cohorts, at a mean of 20.1 months in 1 cohort; EPIC-26
sexual score (1 cohort), EPIC sexual score stratiﬁed by nerve-sparing subgroups only
(1 cohort)
Laparoscopic
or robot-
assisted RP
4 No Dichotomous data: 3 cohorts
Different subscales
2 cohorts reported dichotomous data for potency (number potent); 2 reported return
to baseline for sexual function and sexual bother
Continuous data: 2 cohorts
Both reported data on sexual bother at 12 months
RT 4 No Continuous data: 3 cohorts
Data only available graphically: 1 cohort
No SD or measure of variance: 1 cohort
Dichotomous data: 1 cohort
UCLA PCI:
Sexual
symptoms [84]
RP 6 No Continuous data: 2 cohorts
Data for subgroups only: 1 cohort
No SD or measure of variance: 1 cohort
Dichotomous data: 4 cohorts
Return to baseline sexual function: 3 cohorts, different follow-up times (6 months,
12 months, up to 12 months)
Improvement in erectile function: 1 cohort
6
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depression, anxiety, and coping were only assessed in one or
two cohorts.
It was encouraging to see the marked increase in the use of
validated PROMs since the review in 2004 [5], and in the
domains recommended as core outcomes [7]. Although a
relatively wide range of measures was used, the numbers of
studies using the same measures in the major domains of
interest suggested that meta-analysis should have been
possible. But sufﬁcient pooling could not be achieved for any
outcome because of the poor quality of data collection and
reporting. There were inconsistencies in the presentation of
outcomes – particularly the thresholds and periods of follow-
up; different versions or components of PROMs used or
reported; and incomplete presentation of data to allow
pooling. It was also the case that some studies reported non-
validated measures of urinary (eight cohorts), sexual (ﬁve),
and bowel (one) function. Similar criticisms were made of
studies in previous reviews when fewer PROMs were reported
[5–7]. It is particularly disappointing that the increased use of
validated PROMs does not appear to have improved the
quality of data reporting sufﬁciently to permit adequate
pooling, or even clear qualitative comparison. This means
that any comparisons made or conclusions reached are
subject to considerable bias and uncertainty.
The lack of data relating to active surveillance/monitoring
was conﬁrmed by a review of QoL in this area, which showed
a paucity of data [76]. A study published since we conducted
the searches for our present review used EPIC and SF-12 data
for USA men with low-risk prostate cancer undergoing active
surveillance [77]; more such studies are required. Although
there have been claims that robot-assisted or laparoscopic RP
might have reduced impact on symptomatic outcomes, the
overall summary of results in the present review did not show
this, and this was further conﬁrmed in a recent review of best
practice in RP, which revealed that incontinence and erectile
dysfunction remained signiﬁcant factors [78], with urinary
incontinence still an important issue 60 months after robot-
assisted RP, and rates of sexual dysfunction remaining
comparable to open RP [57].
The most commonly used PROMs across the various
domains were the EPIC, EORTC QLQ and UCLA-PCI
measures, which include urinary, sexual, and bowel symptom
evaluation (the EPIC and EORTC QLQ also include a
hormone domain). Other symptom-speciﬁc measures were
used for assessing urinary function (IPSS, AUASI, ICSMale)
or sexual function (IIEF). Generic QoL was most commonly
assessed by the SF-36, FACT or EORTC QLQ. The major
domains suggested as core outcomes for localised disease are
clear: urinary incontinence, urinary obstruction and irritation,
bowel-related symptoms, sexual dysfunction, and hormonal
symptoms [7]. It is now essential that future studies focus on
these core domains, use the same PROMs, and comply with
recommended methods of presentation and reporting, in
general terms [8] and according to the speciﬁc measures. This
is supported by the recent International Consortium for
Health Outcomes Measurement (ICHOM) [79] initiative,
Table 2 (continued)
Domain Outcome
measure and
reference to
measure
Treatment Number of
cohorts
Meta-
analysis
possible
Reason
Laparoscopic
or robot-
assisted RP
5 No Continuous data: 1 cohort
Dichotomous data: 4 cohorts
3 cohorts provided data on numbers of patients with erection sufﬁcient for
intercourse at 6 months; 2 studies also provided data at 12 and 24 months
1 cohort used different thresholds
IIEF [86] RP 5 No Dichotomous/categorical data: 5 cohorts
Different thresholds: score >19 (1 cohort), ≥22 (1 cohort), ≥15 (1 cohort), 5 categories
(1 cohort), response to question 5 potent or not (1 cohort),
Continuous data: 1 cohort, median only
Bowel EPIC: Bowel
symptoms [83]
RP 4 No Dichotomous data: 1 cohort
Continuous data: 3 cohorts
No SD or measure of variance: 2 cohorts
RT 5 No Continuous data: 4 cohorts
Data only available graphically: 2 cohort
No SD or measure of variance: 1 cohort
Dichotomous data: 1 cohort
QoL SF-36 RP 6 No Dichotomous data: 1 cohort
Continuous data: 5 cohorts
No SD or measure of variance: 2 cohorts
Different version of tool (RAND vs SF-36): 1 cohort
2 cohorts provided data on SF-36 at 6 and 12 months of follow-up
AUASI, American Urological Association Symptom Index; EPIC, Expanded Prostate cancer Index Composite; IIEF, International Index of Erectile Function; SF-36, 36-item short-
form health survey; UCLA PCI, University of California, Los Angeles Prostate Cancer Index.
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which recommended measurement of the EPIC-26 (26-item
short form version) urinary incontinence, irritative/obstructive
bowel, sexual, and hormonal domains, with two additional
questions from the EORTC QLQ-PR25 scale for sexual
symptoms and one from a validated scale on erectile
dysfunction aids. We hope that consistent use of a core set of
outcomes will allow future systematic reviews to estimate
summary effect sizes.
The major RCTs of screening and treatment of localised
prostate cancer are either now in longer follow-up periods
[Scandinavian Prostate Cancer Group Trial Number 4
(SPCG-4) and European Randomised Study of Screening for
Prostate Cancer (ERSPC)] or did not report detailed PROMs in
previous publications [the Prostate, Lung, Colorectal, and
Ovarian cancer screening trial (PLCO) and the Prostate cancer
Intervention Versus Observation Trial (PIVOT)]. The Prostate
testing for cancer and Treatment (ProtecT) trial, funded by the
UK National Institute for Health Research (NIHR) comparing
open RP, EBRT, and active monitoring is due to publish in
2016 with a wide range of PROMs [80].
The strengths of the present review lie in its Cochrane-guided
protocol and methods. The inclusion criteria restricted the
review to larger studies with data on symptomatic and QoL
outcomes after the major treatment modalities, reported at
baseline and up to 60 months after treatment. Data were
extracted to permit meta-analysis, and although it was not
possible to complete this, the data collection strategy enabled
clear identiﬁcation of the weaknesses of the studies’ data
collection and presentation practices. The limitations of the
present review include that some important small studies may
have been missed and that the primary aim, meta-analysis to
permit clarity of presentation of ﬁndings, was not possible. A
further limitation is that we did not conduct a formal risk of
bias assessment of the included studies. However, most of the
included studies were single treatment cohorts all which were
considered at high risk of bias. For the purposes of the
present review, the included RCTs were also considered as
single treatment cohorts as they compared speciﬁc forms of
the same treatment rather than comparing two different
treatment categories (e.g. they compared two forms of BT
rather than comparing BT with RP). The number of multiple
treatment cohorts was too small to allow a formal
comparison of treatments within a single study. Any
comparisons between treatment modalities are therefore based
on evaluations within single treatment cohorts rather than
within study comparisons.
In conclusion, the present review found, as did previous
reviews, that data collection and presentation of the impact of
short-term symptomatic and QoL outcomes after treatment for
localised prostate cancer are of insufﬁcient quality to permit
precise guidance to men about the risks to these aspects of their
lives. Studies now tend to include validated PROMs to assess
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these important aspects, but much greater attention needs to be
paid to collecting, analysing, and reporting these data
according to high quality standards so that they can be
synthesised. As evidence continues to suggest that PSA testing
leads to the identiﬁcation of many tumours that may not need
treatment, and that radical treatments have an impact on
important areas of a man’s life, clear and accurate data about
PROMs becomes even more important for men considering
whether to have a PSA test, or which treatment to have when
diagnosed with localised prostate cancer.
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